Autres langues Elicio Therapeutics, Inc.

Actions

ELTX

US28657F1030

Recherche biotechnologique et médicale

Cours en clôture Nasdaq 05/10/2026			Varia. 5j.	Varia. 1 janv.
1,920 ^USD	0,00%		+3,78%	-75,88%

24/09	Elicio Therapeutics, Inc. annonce de nouvelles analyses préspécifiées de l’étude randomisée de phase 2 AMPLIFY-7P évaluant ELI-002 7P dans l’adénocarcinome canalaire pancréatique réséqué	CI
24/09	Elicio Therapeutics, Inc. : B. Riley reste à l'achat	ZM

Autres langues

24/09	Elicio Therapeutics, Inc. Announces New Pre-Specified Analyses from Randomized Phase 2 AMPLIFY-7P Study Of ELI-002 7P in Resected Pancreatic Ductal Adenocarcinoma
24/09	Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
21/09	Elicio Therapeutics, Inc.(NasdaqCM:ELTX) dropped from S&P Global BMI Index
31/08	Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
31/08	Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
24/08	Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
19/08	Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
13/08	Elicio Therapeutics: Q2 Earnings Snapshot
13/08	Elicio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
13/08	Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
10/08	Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma
10/08	Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma
10/08	Elicio Therapeutics Announces Activation Of Investigator-Initiated Phase 1 Study Of Neoadjuvant ELI-002 7P For Pancreatic Ductal Adenocarcinoma
06/08	Certain Stock Options of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026.
06/08	Certain Restricted Stock Units of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026.
06/08	Certain Pre-Funded Warrants of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026.
06/08	Certain Warrants of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026.
06/08	Certain Common Stock of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026.
06/07	Elicio Therapeutics Closes $15 Million Registered Direct Offering
06/07	Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
02/07	Top Midday Decliners
02/07	Wall Street Set to Open Higher in Thursday Trading; US Adds Only 57,000 Jobs in June
02/07	Top Premarket Decliners
02/07	Elicio Therapeutics Prices $15 Million Direct Offering
02/07	Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering